| Title |
Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients
|
|---|---|
| Published in |
Journal of Thrombosis and Thrombolysis, April 2018
|
| DOI | 10.1007/s11239-018-1658-6 |
| Pubmed ID | |
| Authors |
Maren Hieber, Heiko Hollasch, Dorothee Heck, Mirjam Mächtel, Ulrich Geisen, Wolf-Dirk Niesen, Jochen Brich, Andreas Harloff |
| Abstract |
Dabigatran is a direct thrombin inhibitor and a non-vitamin-K-antagonizing oral anticoagulant, approved for the prevention of stroke and systemic embolization in atrial fibrillation. Idarucizumab is a humanized monoclonal antibody that was recently approved for antagonizing the anticoagulant effects of dabigatran. Here, we report the use of idarucizumab in four acute stroke patients treated with dabigatran in order to enable intravenous thrombolysis in three patients and emergent trepanation in one patient with space occupying subdural hematoma. Since experience on the optimal management of acute stroke patients under medication with dabigatran and on the use of idarucizumab is currently limited, we propose an approach for laboratory testing and fast administration of intravenous thrombolysis and neurosurgery based on our experience. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 28% |
| Researcher | 5 | 16% |
| Student > Ph. D. Student | 3 | 9% |
| Other | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 9 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 38% |
| Business, Management and Accounting | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Psychology | 1 | 3% |
| Neuroscience | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 16 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2018.
All research outputs
#3,970,930
of 23,043,346 outputs
Outputs from Journal of Thrombosis and Thrombolysis
#151
of 992 outputs
Outputs of similar age
#78,247
of 329,299 outputs
Outputs of similar age from Journal of Thrombosis and Thrombolysis
#4
of 17 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 992 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,299 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.